---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-23-000138"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:52:51.723649+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Agios Q3: PYRUKYND rev $7.4M; first patient dosed in Phase 3 sickle cell; net loss $91.3M

## Summary
- PYRUKYND net revenue $7.4M in Q3 2023 (+10% QoQ); 100 patients on therapy, 160 completed enrollment forms.
- First patient dosed in Phase 3 portion of RISE UP pivotal study of mitapivat in sickle cell disease.
- Completed enrollment in Phase 3 ACTIVATE-kidsT; >50% enrolled in Phase 3 ACTIVATE-kids for pediatric PK deficiency.
- Net loss $91.3M in Q3 2023 vs $81.7M in Q3 2022; cash $872.4M as of Sep 30, 2023, funding into 2026.
- Topline data for AG-946 in LR-MDS expected by year-end 2023; Phase 3 thalassemia data in 2024.

## SEC filing metadata
- accession: 0001439222-23-000138
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000138/0001439222-23-000138-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000138/agio-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-23-000138
- JSON: https://secwatch.observer/filing/0001439222-23-000138.json
- Plain text: https://secwatch.observer/filing/0001439222-23-000138.txt

## Key facts
- Earnings Releases
  AGIOS PHARMACEUTICALS, INC. reported third quarter ended September 30, 2023 results: revenue $7.4 million, net income $91.3 million net loss.
  - Period: third quarter ended September 30, 2023
  - Revenue: $7.4 million
  - Net income: $91.3 million net loss
  - Result: reported results
  source text: Data Readouts in Two Phase 3 Trials of Mitapivat in Thalassemia Next Year and Topline Data for AG-946 in LR-MDS by Year-end 2023 – – U.S. PYRUKYND ® (mitapivat) Net Revenue of $7.4 Million in Q3; Cash, Cash Equivalents and Marketable Securities of $872.4 Million as of September 30, 2023 – CAMBRIDGE, Mass., November 2, 2023 -- Agios Pharmaceuticals, Inc. (Nasdaq:
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000138/0001439222-23-000138-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.